In experimental models of NAFLD/NASH, up-regulation of AnxA1 is already evident in fatty livers and further increases with disease progression specifically involving macrophages containing intracytoplasmatic lipid droplets. This evidence concerns the gene ANXA1 and metabolic dysfunction-associated steatohepatitis.